NasdaqGS:IONSBiotechs
Ionis (IONS) Wins Tryngolza Approval And Recordati Deal For Zilganersen
Ionis Pharmaceuticals (NasdaqGS:IONS) received FDA approval for Tryngolza (olezarsen) as the first treatment to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia.
The company plans a U.S. commercial launch of Tryngolza next month, targeting high risk patients with limited existing options.
Ionis also signed a licensing agreement granting Recordati exclusive rights to develop and commercialize zilganersen for Alexander disease outside the U.S.,...